All News

Sanofi's stock plummets over 10% as Amlitelimab's Phase III trial results raise concerns about the company's future pipeline and Dupixent's patent expiration.

These drugs have quickly become household names due to their popularity as weight loss medications.

SeqOne's acquisition of Congenica enhances its AI-driven genomic solutions, expanding global reach and transforming genetic data analysis for personalized medicine.

Novo Nordisk reveals Wegovy's 57% greater risk reduction for heart attack and stroke compared to Tirzepatide in obese patients at ESC Congress.

The two companies issued statements detailing the number of studies about the vaccines’ impact.

As more companies announce layoffs and other restructuring plans, industry experts are asking what will happen next.

Pharmaceutical Executive Daily highlights Pfizer's defense of vaccine data integrity, insights on GLP-1 investments, and Novartis' $5.2 billion acquisition of Argo Biopharmaceuticals.

The company pointed the President to existing published research and pledged to post more to its site.

Enlaza Therapeutics partners with Vertex Pharmaceuticals to advance innovative therapies for autoimmune diseases using War-Lock technology, enhancing treatment options.

OMass Therapeutics partners with Genentech to advance innovative treatments for inflammatory bowel disease, leveraging their unique OdyssION drug discovery platform.

The feature will be available on the company’s platform Nuro.

FDA approves Leqembi Iqlik as a weekly subcutaneous injection for Alzheimer's treatment, enhancing patient convenience and safety in care.

Wayrilz is the first Bruton’s tyrosine kinase inhibitor to be approved for adults with persistent or chronic immune thrombocytopenia who have not responded adequately to prior therapy.

Johnson and Johnson halts Nipocalimab's development for rheumatoid arthritis after Phase 2a trial shows no significant benefits over existing therapies.

The blood purification technology is used for the treatment of severe treatment-refectory systematic lupus erythematosus (SLE).

Lilly has temporarily halted UK shipments of Mounjaro until Sept. 1, when new list prices take effect.

Outlook Therapeutics faces FDA hurdles for Lytenava's approval in wet AMD, seeking clarity on efficacy requirements while expanding globally.

A monthly roundup of business and people news in the pharmaceutical industry.

Replicate Bioscience partners with Novo Nordisk to advance self-replicating RNA therapies for obesity and type 2 diabetes, enhancing innovative treatment options.

Amylyx Pharmaceuticals halts Amx0035's Orion program for PSP, shifting focus to Avexitide and other promising treatments for neurodegenerative diseases.

Lawyers for Monarez argue that only the president can fire her and that she has no plans to resign.

Bayer's Gadoquatrane, a low-dose MRI contrast agent, aims to enhance imaging safety and efficacy for chronic disease patients, pending FDA approval.

FDA approves COVID-19 vaccines from Moderna, Pfizer-BioNTech, and Novavax targeting the LP.8.1 sublineage of SARS-CoV-2, with eligibility limited to adults aged 65 years and older and those with underlying medical conditions that place them with a high risk for severe disease.

ACOG reaffirms support for COVID-19 vaccines during pregnancy, challenging recent CDC recommendations and emphasizing maternal and fetal health.

Pfizer initiates layoffs at its Bothell site as part of a broader cost-cutting strategy, aiming to enhance R&D efficiency and automation.

The merger integrates EVERSANA’s commercialization services with Waltz Health’s AI-powered payer tools to address patient affordability, streamline drug access, and reduce costs for high-expense therapies such as GLP-1s.

Eli Lilly's oral GLP-1 receptor agonist Orforglipron showed significant weight loss, A1C reduction, and cardiometabolic improvements in the Phase III Attain-2 trial, paving the way for global regulatory submissions.

Putnam’s CEO discusses advancements in oncology and how companies are working to ensure patients have access to these new treatments.